Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
How Has the Low-Grade Glioma Market Grown from 2024 to 2025?
In recent years, there has been solid growth in the market size of low-grade glioma. The market is projected to expand from $1.39 billion in 2024 to $1.48 billion in 2025, with a compound annual growth rate (CAGR) of 6.1%. The surge in the past period can be linked to enhanced awareness of brain tumors, increased investment in oncology-related research, a rise in the number of designated orphan drugs, the broadening of telemedicine, and improved access to healthcare.
What Growth Rate Is Anticipated for the Low-Grade Glioma Market in the Coming Years?
The market for low-grade gliomas is projected to experience significant expansion in the coming years, becoming a staggering $1.86 billion industry by the year 2029 with a Compound Annual Growth Rate (CAGR) of 5.9%. This anticipated growth through the forecast period is likely due to demographic shifts toward an older population, increasing healthcare expenses, a higher frequency of brain tumors, proliferating governmental initiatives, and a surge in instances and prevalence of high-grade gliomas. Notable market trends in the forecast period encompass progress in imaging technologies, the development and introduction of radiation treatments and chemotherapy regimens, increased clinical trial activity, and the inclusion of immunotherapy.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21215&type=smp
Who Are the Leading Companies in the Low-Grade Glioma Market?
Major companies operating in the low-grade glioma market are McKesson Corporation, F. Hoffmann-La Roche Ltd, Merck & Co. Inc., Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, Daiichi Sankyo Company Limited, Ipsen S.A., BeiGene Ltd., NovoCure Limited, Les Laboratoires Servier, Day One Biopharmaceuticals Inc., CStone Pharmaceuticals Co. Ltd., AnHeart Therapeutics Inc., Apollomics Inc., Agios Pharmaceuticals Inc., BioMed Valley Discoveries Inc., Avistone Biotechnology Co. Ltd., NextSource Biotechnology LLC, Sunesis Pharmaceuticals Inc.
What Are the Key Drivers of the Low-Grade Glioma Market?
The upward trend in brain tumor occurrences is anticipated to stimulate the expansion of the low-grade glioma market. Brain tumors, a growth of abnormal cells in the brain or adjacent areas, can either be harmless or malignant. This surge in brain tumor incidences could be attributed to factors such as heightened exposure to radiation, environmental toxins, genetic predisposition, and aging. Low-grade glioma serves as a beneficial tool in brain tumor treatment primarily utilizing avant-garde diagnostic methods and specific treatments such as surgery, radiation and chemotherapy. These techniques aid in decelerating tumor progression, conserving neurological function, and enhancing patient outcomes thereby emphasizing the importance of early detection and personalized treatment in managing other brain tumors exhibiting similar growth behaviours. For instance, as per The Central Brain Tumor Registry of the United States (CBTRUS) – a non-profit organization based in the US, in October 2023, it was reported that in 2022, the global incidence rate of primary malignant brain tumors was roughly 3.5 per 100,000, with elevated rates in high-income countries (4.9 per 100,000) as opposed to low-middle (2.4 per 100,000) and low-income countries. Consequently, the escalating incidences of brain tumors are propelling the expansion of the low-grade glioma market.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=21215&type=smp
What Are the Key Market Segments in the Low-Grade Glioma Industry?
The low-grade glioma market covered in this report is segmented –
1) By Drug Type: Trametinib, Dabrafenib, Ivosidenib, Mirdametinib
2) By Treatment: Surgery, Chemotherapy, Radiation
3) By Route Of Administration: Topical, Oral
4) By Distribution Channel: Online Pharmacies, Hospital Pharmacies, Retail Pharmacies
What Are the Latest Trends in the Low-Grade Glioma Market?
Top-tier corporations in the low-grade glioma industry are leveraging the merger of combination therapies and targeted remedies, such as drugs altering genetic composition, to consolidate their market stand and improve treatment procedures for pediatric patients with low-grade glioma. Genetic alteration medications serve as targeted remedies intended to change or suppress specific genetic irregularities or mutations in cells, thereby aiding in treating conditions like cancer by obstructing the routes that fuel unchecked cell multiplication. For example, in May 2024, Day One Biopharmaceuticals, a biotech organization based in the United States, unveiled Tovorafenib (Ojemda) following express FDA approval. This target-based treatment is meant for children aged six months and above diagnosed with inoperable or recurrent low-grade glioma (LGG) having BRAF gene alterations. Offering an adaptable single-weekly oral therapy, it responds to an essential need for pediatric LGG patients with previously limited treatment choices.
Access The Full Report Here:
https://www.thebusinessresearchcompany.com/report/low-grade-glioma-global-market-report
What Are the Key Regional Markets in the Low-Grade Glioma Industry?
North America was the largest region in the low-grade glioma market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the low-grade glioma market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Purchase The Full Report Today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21215
This Report Delivers Insight On:
1. How big is the low-grade glioma market, and how is it changing globally?
2. Who are the major companies in the low-grade glioma market, and how are they performing?
3. What are the key opportunities and risks in the low-grade glioma market right now?
4. Which products or customer segments are growing the most in the low-grade glioma market?
5. What factors are helping or slowing down the growth of the low-grade glioma market?
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 2071930708
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model